On one hand, K-Ras silencing inhibited EMT and proliferation of breast cancer cells, while promoting apoptosis, but these effects were reversed when mutant cells were treated with a PI3K/AKT agonist [99]. This evidence concerns the gene PIK3CD and breast carcinoma.